Background. We evaluated the impact of extended azithromycin (1.5g over 5 days) on selection of macrolide resistance and microbiological cure in men with Mycoplasma genitalium urethritis during 2013-2015 and compared this to cases treated with azithromycin 1g in 2012-2013.
Mycoplasma genitalium causes approximately 15%-25% of nongonococcal urethritis (NGU) cases in men [1] . A single 1g dose of azithromycin has been a common treatment for NGU. However, since 2006, multiple countries have reported increasing failure rates of azithromycin 1g for infections due to M. genitalium [2] [3] [4] . Lau et al recently reviewed 21 studies of the efficacy of azithromycin 1g for M. genitalium in 1490 people and reported that the average cure rate has fallen from 85% (95% confidence interval [CI] , 82%-88%) in studies performed from 1999 to 2008 to 67% (95% CI, 57%-77%) for studies performed from 2009 to 2013 [5] .
In Melbourne, Australia, in 2012-2013, azithromycin 1g cured 61% of 155 genital M. genitalium infections (69% were NGU). Macrolide resistance mutations (MRMs) were found in 36% of pretreatment samples and were strongly associated with azithromycin failure [6] . Importantly, post-treatment MRMs were detected in 11% of genital M. genitalium cases infected with initially susceptible strains, suggesting the selection of resistant strains during treatment with azithromycin 1g. The selection of resistance in the setting of widespread use of single-dose azithromycin 1g for the slow-growing M. genitalium and its associated syndromes may explain why rising rates of circulating MRMs are now greater than 30% in many countries [7] . Recent European guidelines recommend a 5-day course of azithromycin 1.5g, dosed 500 mg initially, then 250 mg for another 4 days for M. genitalium [8] . Three nonrandomized Swedish studies have reported high proportions cured with this extended 1.5g regimen when compared to azithromycin 1g or when stratified by pretreatment macrolide resistance [9] [10] [11] . When data from the 2 studies reporting pretreatment macrolide resistance are pooled, extended azithromycin failed
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and MRMs were subsequently detected in 3/71 (4.2%; 95% CI, 0.9%, 11.9%) [9, 11] .
Based on these preliminary data, in October 2013 the Melbourne Sexual Health Centre (MSHC) began treating men with NGU with a 5-day course of azithromycin 1.5g (500 mg initially followed by 250 mg daily for 4 days) to determine if this improved cure rates by reducing the rate of emergence of MRMs during treatment. Here, we report treatment outcomes and the proportions of cases with MRMs before and after treatment with azithromycin 1.5g and compare this with data from the preceding period in 2012-2013 in which all men with M. genitalium-associated NGU received azithromycin 1g.
METHODS
MSHC is the only public clinic that treats sexually transmitted infections (STIs) in Melbourne. The center diagnoses approximately 1500 cases of NGU in men each year. Clients provide basic sexual behavioral data at arrival. These data, along with clinical notes and laboratory results, are stored in an electronic clinic database. Using this database, we identified all cases of M. genitalium in men with NGU diagnosed at MSHC from 1 October 2013 to 30 June 2015. Cases from 1 July 2012 to 30 June 2013 and treated with azithromycin 1g were used as historical controls and identified in the same way. Members of the research team extracted the following data from electronic medical records: date of presentation, presence of urethral symptoms, date of M. genitalium test, type of antibiotic treatment, prior antibiotic prescribed for this episode, result of test of cure, genital symptoms after treatment, risk of reinfection (sex after treatment with untreated partners), and documentation of poor adherence. Only men with NGU (defined as up to 1 month of urethral symptoms such as discharge, discomfort, or dysuria) treated with extended azithromycin 1.5g (or 1g for controls) and with urethral/ urine samples positive for M. genitalium were included in the analysis. The Alfred Hospital Ethics Committee approved the study (no 304/15).
Laboratory Methods
Extracted DNA from pre-and post-treatment specimens with M. genitalium detected was stored at -30°C. Samples from the study period were processed as described previously; samples from April 2014 to September 2014 were not available for analysis [6] . A M. genitalium-specific polymerase chain reaction (PCR) targeting the 16S ribosomal RNA gene was used to detect M. genitalium DNA [12] . Mycoplasma genitalium load was subsequently determined on all positive samples as described previously [6] . Sanger sequencing was used to determine MRMs at positions 2058 and 2059 (Escherichia coli numbering) in the 23S rRNA gene of M. genitalium on all pretreatment and persistently positive post-treatment samples [4] .
Statistical Methods
The analysis of microbiological cure was restricted to men who were retested (test of cure) for M. genitalium 14-100 days after the start of treatment. Positive tests of cure were defined as treatment failures and negative tests as cures. Proportions cured and proportions with post-treatment resistance were calculated, and 95% CIs were calculated using the binomial exact distribution. P values for proportions were calculated using Fisher exact test or Wilcoxon rank-sum test for medians. Bacterial load was log transformed, and significance of comparisons was assessed using t test. Odds ratios (ORs) and 95% CIs for predictors of treatment failure were calculated from a logistic regression model using the group analyzed for microbiological cure, adjusted for potential confounders in the multivariate model.
To determine if the proportion of men with urethritis in whom resistance was selected during treatment with extended azithromycin 1.5g (wild-type pre-treatment and MRMs detected post-treatment) differed from the proportion of men given a single dose of 1g, we performed a historical comparison using controls from a series of patients with M. genitalium treated at MSHC with azithromycin 1g in 2012 and 2013 [6] . As the current analysis of azithromycin 1.5g is restricted to men with NGU, we excluded women and asymptomatic men from the historical dataset to ensure comparable populations. Using the 2-sample Z test for proportions, we compared proportions with pre-treatment and selected resistance and treatment outcomes between the 2 groups. The 106 cases in the 2013-2015 group gave 82% power to detect a 14% increase in the proportion cured (P = .05). Statistical calculations were performed using Stata, version 13.
RESULTS
From 1 October 2013 to 30 June 2015, 215 men with NGU had positive tests for M. genitalium. Of these, 169 were treated with azithromycin 1.5g and 98/169 had sufficient stored sample for 23S MRM genotyping ( Figure 1 ). Of the 169 men, 143 (85%) returned to the clinic and 106 (63%) had a test of cure 14-100 days after starting treatment (median, 36 days; intraquartile range, 29-52). Sixty-three had both genotyping of pre-and post-treatment M. genitalium specimens and a test of cure 14-100 days after treatment.
Characteristics of Participants
Of the 106 men with M. genitalium urethritis who received azithromycin 1.5g and returned for test of cure, 41 (38%) were men having sex with men (MSM) ( Table 1) . MSM were older, reported more partners, and were less likely than heterosexual men to report sexual partners outside Australia (19% compared to 55%; P = .002). MSM were twice as likely to have MRMs detected in pre-treatment samples (76% compared to 39%; P = .005). c Rank-sum test.
d Denominator varies because not all patients provided behavioral data.
e Fisher exact test.
f Denominator varies because only 98 stored pre-treatment samples were tested for macrolide resistance mutations (see Figure 1 ).
Treatment Outcomes Following Extended Azithromycin 1.5g Compared to 1g
In the primary analysis of 106 men with tests of cure at 14-100 days, 62 (58%; 95% CI, 49%, 68%) were microbiologically cured. For MSM, the proportion cured was 14/41 (34%; 95%CI, 20%, 50%), lower than in heterosexual men for whom the proportion cured was 48/65 (74%; 95% CI, 61%, 84%; P < .001; Table 2 ). Recurrent or persistent urethral symptoms (discharge, burning, dysuria) at the time of test of cure were more common in patients who did not achieve microbiological cure (34/44; 77%; 95% CI, 62%, 89%) compared to those who did (10/63; 16%; 95% CI, 8%, 28%; P < .001).
To determine if proportions cured differed between extended azithromycin 1.5g and single-dose azithromycin 1g, we compared the current dataset (2013-2015) with a dataset of males with M. genitalium urethritis who received 1g (2012-2013), 97% of whom returned for assessment before our treatment protocol changed [6] . There was no significant difference in proportions cured by azithromycin 1.5g (58%; 95% CI, 49%, 68%) compared to azithromycin 1g (52%; 95% CI, 42%, 62%; P = .34; Table 3 ). Pretreatment macrolide resistance was detected in 52% (95% CI, 42%, 62%) of males with M. genitalium urethritis in 2013-2015 and in 44% (95% CI, 34%, 54%) of males with M. genitalium urethritis in 2012-2013 (P = .25). While the prevalence of pretreatment resistance was the same in heterosexual males in the 2 time periods (39% and 40%, respectively; P = .9), it was higher in MSM in 2013-2015 (76%) compared to MSM in 2012-2013 (53%; P = .05). Proportions cured were the same for both regimens in those with pretreatment resistance (14% and 15%; P = .9) and in those without (82% for each regimen; P = 1.0).
Macrolide Resistance
MRMs were detected in 51 of 98 genotyped pre-treatment samples (52%; 95% CI, 42%, 62%). Treatment outcomes are shown in Table 4 by pre-treatment genotype. In the 63 cases who were genotyped and analyzed for microbiological cure (Figure 1 ), pre-treatment MRMs were detected in 81% of cases who experienced microbiological failure and in 12% of cases who appeared microbiologically cured (P < .001).
Six patients with wild-type infections had persistent infection after treatment; only 4 of these post-treatment samples were available for genotyping. MRMs were detected in all 4 at test of cure, meaning the proportion of wild-type infections with post-treatment resistance was 4/34 (12%; 95% CI, 3%, 27%). Sexual histories of the 6 men with wild-type treatment failures indicate that reinfection was more likely in one man who resumed sex with a partner treated with the same regimen; his post-treatment sample was not sequenced (Supplementary Table 1 ). Of wild-type cases treated with 1g azithromycin in the historical control group, post-treatment MRMs were detected in 18% (95% CI, 10%, 30%), which was not significantly (P = .4) greater than the 12% (95% CI, 3%, 27%) of cases with post-treatment MRMs after extended azithromycin 1.5g. Of 29 cases with pre-treatment MRMs, 4 appeared to be cured (14%; 95% CI, 8%, 35%; Table 2 ). These men were asymptomatic when they returned for test of cure (range, 32-95 days post-treatment), and none returned with further symptoms that would suggest an initial false-negative
Bacterial Load
Bacterial load was examined in patients stratified by pre-treatment MRMs and treatment outcomes. The 6 wild-type infections that were not cured had significantly higher pre-treatment bacterial loads (mean log 10 4.6) compared to the 28 wild-type infections (mean log 10 3.2) that were cured (P = .02; Figure 2 ), indicating organism load may play a role in selected resistance. The 4 macrolide-resistant infections that were cured had lower pre-treatment bacterial loads (mean log 10 1.6) than the remaining 25 macrolide-resistant infections (mean log 10 3.1) that persisted (P = .04). The mean pre-treatment bacterial load was lower in resistant (log 10 2.9) than in wild-type (log 10 3.4) infections but not significantly so (P = .06; Figure 3a) . In cases who experienced treatment failure, the bacterial load was lower in post-treatment samples (mean log 10 2.2) than in pre-treatment samples (log 10 3.3; P < .01; Figure 3b ). Post-treatment load was measured in 4 of the 6 wild-type treatment failures, and the mean was 2.6 log 10 lower than the mean pre-treatment load (P = .01). In each of the 4 cases, it was at least 1.5 log 10 lower than the corresponding pre-treatment load.
Predictors of Treatment Failure
In univariate analysis, failure of extended azithromycin 1.5g was associated with the following: pre-treatment resistance, reporting male sexual partners, number of sexual partners, and prior use of azithromycin for this NGU episode (Table 5) . Treatment failure was not associated with the following: sex outside Australia, bacterial load, and risk of reinfection. In multivariate analysis, factors that remained significantly associated with treatment failure were pre-treatment resistance (adjusted Abbreviation: CI, confidence interval, N = total number, n = number with characteristic. a Data differ from the series published by Bissessor et al [6] because this analysis was restricted to males with nongonococcal urethritis.
b Study populations were compared using the 2-sample Z test for proportions.
c Includes bisexual men.
d Proportion of initially wild-type infections with positive test of cure and macrolide mutation detected.
e Treatment failed in 6/34 wild-type infections, but post-treatment samples were only available for genotyping in 4 of these. 
DISCUSSION
Increasing the dose and duration of azithromycin to 1.5g over 5 days for the treatment of NGU did not increase the proportion of M. genitalium infections that were cured and did not reduce the rate at which MRMs were detected after treatment. Half of all M. genitalium infections in Melbourne are now resistant to macrolides; this is significantly more common in MSM in whom three quarters of infections are resistant. Infections that persisted despite treatment tended to have a higher pre-treatment bacterial load, and MRMs were detected in post-treatment samples, even if they were initially wild-type infections. These findings raise the question whether continued widespread use of azithromycin for NGU in either dosage regimen will result in a gradual increase in the proportion of macrolide-resistant M. genitalium infections. Management algorithms for NGU that account for resistant M. genitalium must now be developed. This is the largest study to report outcomes of treating M. genitalium with 1.5g extended azithromycin and the only study to evaluate this regimen restricted to a single anatomical site and incorporating bacterial load and resistance mutations. However, it is a retrospective study with incomplete resistance data and incomplete follow-up; 15% of otherwise eligible men did not return for a test of cure. So, it is possible that men who were cured were less likely to return. The pre-treatment genotypes in >60% of the men who did not return show MRMs, implying a likely lower cure rate in this group and that we have not overestimated the failure rate. The OR for treatment failure with MRMs was 24, so the failure rate in this analysis is greatly influenced by the high proportion with resistance, meaning this finding will not be generalizable to populations in which resistance is less common. We cannot exclude the possibility that some apparently wild-type infections included undetected minority populations with MRMs. Nor can we be sure that some of the treatment failures were not reinfections. The sexual histories of those with wild-type infections (Supplementary Table 1 ) whose treatment failed suggest reinfection was unlikely for the majority. A number of other observations in these cases argue against reinfection and are more in favor of selected resistance. First, the genotype has changed from wild type to include MRMs in every case and there are no wild-type infections as we might expect with some reinfections. Second, the bacterial load is at least 1.5 log lower in each post-treatment sample compared to pre-treatment samples. Finally, in univariate analysis, there is no association between treatment failure and the reported risk of reinfection.
Extended azithromycin 1.5g did not significantly increase the proportion of M. genitalium urethritis cases cured (58%) compared to historical controls treated with a single dose of 1g at the same center 2 years previously (52%). Proportions cured using each regimen were identical for macrolide-susceptible and macrolide-resistant infections. This contrasts with findings from 7 studies of extended azithromycin 1.5g for M. genitalium in which 332 of 386 individuals (86%) had negative tests of cure [9] [10] [11] [13] [14] [15] [16] . The higher proportion of treatment failures in our study is likely due to the higher proportion with pre-treatment macrolide resistance (52%) compared to most other studies and is consistent with a global trend of increasing resistance [7, 17] . The proportion with post-treatment resistance (12%; 95% CI, 3%, 27%) is also somewhat higher than the 4.2% (95% CI, 0.9%, 11.9%) in the 2 Swedish studies noted earlier [9, 11] , nevertheless this difference is not significant (P = .15).
It was hoped that the extended azithromycin 1.5g regimen would reduce the selection of MRMs in those wild-type M. genitalium infections in which treatment failed; this regimen is now being recommended for NGU in European treatment guidelines [8] . However, in Melbourne, resistance appeared to be selected in similar proportions of wild-type infections (18% after 1g and 12% after 1.5g), regardless of the use of a single dose or 5-day regimen.
The wild-type infections that persisted and became macrolide resistant tended to have higher pre-treatment bacterial loads, and the resistant infections that were cured tended to have lower loads. However, bacterial load was not a significant predictor of treatment outcome, possibly due to the small number of cases where outcome was not already predicted by pre-treatment genotype. Russian men with urethritis due to M. genitalium (all wild type) were monitored for the disappearance of M. genitalium DNA after receiving the macrolide josamycin [18] . Mycoplasma genitalium DNA persisted for the longest period of time in the 13% of men with the highest pre-treatment bacterial load, leading to treatment failure and selection of MRMs in half of this group but not in those with lower bacterial loads. We also observed a reduction in bacterial load after failed treatment. In other studies where extended azithromycin 1.5g performed well, some patients were previously treated with doxycycline, which usually fails to eradicate M. genitalium [9, 10] . It is plausible that prior treatment with doxycycline reduced bacterial load and increased the likelihood of success with a second antibiotic. Most MSM with M. genitalium urethritis in Melbourne already have a resistant infection, and there seems to be little value in treating these men with either dosage regimen of azithromycin without a negative test for MRMs. It is unclear why resistance is so high in this group. However, the high prevalence of other STIs for which azithromycin is used alone or in combination suggests that M. genitalium circulating in this population is more likely to be exposed to this selective pressure [19] . MSM also appear to have a higher prevalence of antibiotic-resistant Neisseria gonorrhoeae, perhaps for similar reasons [20, 21] .
The implications of the findings in this study are, first, that extended azithromycin 1.5g has no advantage over the single 1g dose and is unlikely to stem the rise of macrolide resistance. Second, a high bacterial load may favor the selection of MRMs and some resistant infections with low bacterial load may still be cured. After treatment failure, persistent infections have lower bacterial loads, so it is possible that an antibiotic sequence or combination could exploit this, whereby one antibiotic lowers load and increases the efficacy of the other antibiotic. Alternative classes and combinations of antibiotics are required for M. genitalium, and the development of rapid point of care tests and tests that identify MRMs will improve our selection and stewardship of available antibiotics. In the meantime, clinical services need to decide how to manage NGU and pelvic inflammatory disease where azithromycin remains effective for Chlamydia trachomatis, but where resistant M. genitalium is increasingly likely to be present.
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